Primary epithelial ovarian carcinoma in Taiwanese women

Purpose of investigation: Primary epithelial ovarian carcinoma is common in industrial countries but rare in the Orient. In fact, it is still a rare disease in Taiwan. In this article, we report the general data of Taiwanese patients with primary epithelial ovarian carcinoma.

Methods: In this retrospective study we used univariate and multivariate analysis models to analyze the prognosis of patients with surgically confirmed primary epithelial ovarian carcinoma. One hundred and ninety-four patients from 1990 to 1996 were identified and enrolled in this study.

Results: The mean follow-up time was 44.7 months with an interval between 15.1 months and 105.9 months. Univariate analysis showed postmenopausal status, advanced stage, presence of lymph node metastasis, poor differentiation, and suboptimal surgery as risk factors for disease recurrence and subsequent deaths. Multivariate analysis demonstrated stage as the most important factor correlated with recurrent disease (risk ratio: 7.303 and 5.409, respectively), followed by optimal surgery (RR: 2.447), and cellular differentiation (RR: 1.677).

Conclusions: Our data on the Taiwan population were consistent with other reports of different races. Early detection for primary epithelial ovarian cancer is of great importance because stage is still the most important predictor in disease-free survival and disease-related deaths. Application of the most reliable and acceptable methods of screening is our goal in the next century after weighing benefits over costs.

Epithelial ovarian carcinoma; Multivariate and univariate analyses; Prognosis

[1] OzolsR . F..R ubin S. C.. Thoma、 G. M.,R obboy S. J.: "Epithelial ovarian cancer". In: Hoskins W. J., Perez C. A., Young R. C., eds·'Principle and Practice of Gynecologic Oncology". 2nd ed. Philadelphia: Lippincott-Raven Press, 1997, 919.

[2] Friedlander M. L.:''Prognostic factors in ovarian cancer." Semin Oncol., 1998, 25, 305.

[3] DiSaia P. J., Creasman W. T.: "Epithelial ovarian cancer." In DiSaia P. J., Creasman W. T., eds. "Clinical Gynecologic Oncology", 5th ed. St. Louis: Mosby-Year Book Inc., 1997, 282.

[4] SAS/STAT user's guide, release 6.03 ed山on. Cary (NC), SAS Institute, 1988.

[5] Kaplan E. L., Meier P.: "Non-parametric estimation from mcomplete observation." J. Am. Stat. Assoc., 1986, 4, 57.

[6] Mantel N.: "Evaluation of survival data and two rank-order statistics arising in its consideration". Cancer Chemother. Rep.. 1966, 50, 163.

[7] Cox D.R.: "Regression model、and life tables". J. Roy. Stat. Soc B., 1972, 34, 187.

[8] Young R. C., Walton L. A., Ellenberg S. S., Homesley H. D., Wilbanks G. D.. Decke D. G., et al.: "Adjuvant therapy in stage I and II epithelial ovarian cancer: results of two prospective randomized trials". N. Engl..T. Med., 1990, 322, 1021.

[9] Krag K. J., Canellos G. P., Griffiths C. T., KnappR. C., Parker L M., Welch W.R. et al.: "Predictive factors for long term survival in patients with advanced ovarian cancer". Gynecol. Oncol.. 1989, 34, 88.

[10] Tempfer C., Obermair A., Hefler L., Haeusler G., Gitsch G., Kainz C.: "Vascular endothelial growth factor serum concentrations in ovarian cancer". Obstet. Gynecol., 1998, 92, 360.

[11] Reles A. E., Gee C., Schellschrnidt I., Schmider A., Unger M., Friedmann W. et al.: "Prognostic significance of DNA content and S-phase fraction in epithelial ovarian carcinomas analyzed by image cytometry". Gynecol. Oncol., 1998, 71, 3.

[12] Curling M., Stenning S., Hudson C. N., Watson J. V.: "Mullivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer.·· J. Clin. Pathol., 1998, 51,455.

[13] Tsumura N., Sakuragi N., Hareyama H., Satoh C., Oikawa M., Yamada H. et al.: "Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma". Int. J. Cancer. 1998, 79, 526.

[14] Zwart J., Geisler J. P., Geisler H. E.: "Five-year survival in patients with endometrioid carcinoma of the ovary versus those with serous carcinom‘’． Eur. J. Gynecol. Oncol.. 1998, 19, 225.

[15] Trope C. G., Vergote J. K. I.: "Prognostic factors in platinum-res!slant ovarian carcinoma treated with ifosfamide-etoposide". Eur. J. Gynecol. Oncol., 2000, 21, 255.

[16] Jacobs I., van Nagell J. R. Jr., DePriest P. D.:'"Screening for epithelial ovarian cancer". ln: Gershenson D. M., McGuire W. P., eds. "Ovarian Cancer: Controversies in Management''. New York, Churchill Livingstone, 1998,1.

[17] Eisen A.. Rebbeck T. R., Wood W. C., Weber B. L.: "Prophylactic surgery in women with a hereditary predisposition to breast and ovarian cancer". J. Clin. Oncol., 2000, 18, 1980.

[18] Wang P.H., Shyong W. Y., Li Y. F., Lee H. H., Tsai W. Y., Chao H. T., Wu C. Y. et al.: "BRCA I mutations in Taiwanese with epithelial ovarian carcinoma and sporadic primary serous peritoneal carcinoma". lap. J. Clin. Oncol., 2000, 30, 343.

[19] Wang P.H., Yuan C. C., Shong W. Y., Chiang S. C., Chao J. Y., Yen M. S., Ng H. T.: "Optimal debulking surgery seems to be an independent prognostic factor in patients with FIGO IIIC primary epithelial ovarian carcinoma". Chin. Med. J. (Taipei), 2000, 63, 220.

[20] Hoskins W. J., McGuire W. P., Brady M. F.,H omesley H. 0., Creasman W. T., Berman M. et al.:'The effect of diameter of the largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1994, 170, 974.

[21] Eisenkop S. M., Nalick R.H., Wang H.J., Teng N. N.: "Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival". Gynecol. Oneal. 1993, 51, 224.

[22] Griffiths C. T.: "Surgical resection of the tumor bulk in the primary treatment of ovarian carcinoma". Natl. Cancer. Inst. Monogr., 1975, 42, 101.

[23] Griffiths C. T.: "Surgery at the time of diagnosis m ovanan cancer". In: Blackledge G., Chan K. K., eds.“Management of Ovarian Cancer", London, Butterworths, 1986, 60.

[24] Morton D. L.: "Changing concepts in cancer surgery: surgery as immunotherapy". Am. J. Surg., 1978, 135, 767.

[25] Brinkhuis M., Meijer G. A., Baak J. P.: "An evaluation of prognostic factors in advanced ovarian cancer". Eur. J. Obstet. Gynecol. Reprod. Biol., 1995, 63, 115.

[26] Hoskins W. J., Bundy B. N., Thigpen J. T., Omura G. A.: "The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study". Gynecol. Oncol., 1992, 47, 159.

[27] Krag K. J., Canellas G. P., Griffiths C. T., Knapp R. C., Parker L M., Welch W. R. et al.: "Predictive factors for long term survival in patients with advanced ovarian cancer". Gynecol. Oncol., 1989, 34, 88.

[28] BerekJ . S.: "Epithelial ovarian cancer". In: BerekJ . S.,H acker N. F., eds. "Practical Gynecologic Oncology", 2nd ed. Baltimore, Williams & Wilkins Co., 1994, 327.

[29] Wang P. H., Yang T. Z., Lee W. L., Chang S. P., Chao H. T., Yuan C. C.: "Treatment of infertile women with adenomyosis with a conservative microsurgical technique and a gonadotropin-releasing hormone agonist". Fertil. Steril., 2000, 73, 1061.

[30] Sert M. B., Abbas F. M., Currie J. L., Zahyrak M. L., Rosenshein N. B.: "Use of the ultrasound surgical aspirator in ovarian cancer a case-control study". Eur. J. Gynecol. Oneal., 2000, 21, 24.